In Re Factor VIII or IX Concentrate Blood Products Liability Litigation

595 F. Supp. 2d 855, 2009 U.S. Dist. LEXIS 3023, 2009 WL 89873
CourtDistrict Court, N.D. Illinois
DecidedJanuary 14, 2009
DocketMDL No. 986. No. 93 C 7452
StatusPublished

This text of 595 F. Supp. 2d 855 (In Re Factor VIII or IX Concentrate Blood Products Liability Litigation) is published on Counsel Stack Legal Research, covering District Court, N.D. Illinois primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
In Re Factor VIII or IX Concentrate Blood Products Liability Litigation, 595 F. Supp. 2d 855, 2009 U.S. Dist. LEXIS 3023, 2009 WL 89873 (N.D. Ill. 2009).

Opinion

MEMORANDUM OPINION AND ORDER

(Ruling on Taiwan Forum Non Conveniens Motion)

JOHN F. GRADY, District Judge.

This multidistrict litigation consists of claims against the defendant pharmaceutical companies by citizens of various foreign countries who suffer from hemophilia. The plaintiffs allege that they contracted the HIV and/or Hepatitis C(HCV) viruses from using contaminated blood products manufactured by one or more of the defendants. The products were derived by the defendants from the plasma of paid blood donors and processed by the defendants into blood-clotting “factor concentrates” which could be infused by hemophiliacs. Plaintiffs allege that the viral contamination of the concentrates resulted from a number of negligent acts and omissions of the defendants in the collection and processing of the blood plasma. A further allegation is that after the defendants discovered the contamination, they withdrew the defective concentrates from distribution in the United States but continued to distribute them in foreign countries for use by unsuspecting foreign citizens, causing them to contract the HIV and/or HCV viruses.

The defendants deny the allegations in the complaints and, in addition, are moving to dismiss each of the cases on the ground of forum non conveniens. We have granted the defendants’ motion in regard to the claims of citizens of the United Kingdom, In re Factor VIII or IX Concentrate Blood Products Liability Litigation, 408 F.Supp.2d 569 (N.D.Ill.2006), aff'd, In re *859 Factor VIII or IX Concentrate Blood Products Litigation, 484 F.3d 951 (7th Cir. 2007); Argentina, In Re Factor VIII or IX Concentrate Blood Products Litigation, 531 F.Supp.2d 957 (N.D.Ill.2008) (presently on appeal); and Israel, In Re Factor VIII or IX Concentrate Blood Products Liability Litigation, 2008 WL 4866431 (N.D.Ill. June 4, 2008) (presently on appeal).

The history of the litigation is recounted in our United Kingdom decision, 408 F.Supp.2d at 570-73. The present opinion is addressed to the motion of two of the four multidistrict defendants, Bayer Corporation and Baxter Healthcare Corporation, to dismiss the three complaints brought against them by citizens of Taiwan on the ground of forum non conveniens. The three complaints, involving a total of 37 individual plaintiffs, were filed in the United States District Courts for the Northern and Central Districts of California and transferred here by the Judicial Panel on Multidistrict Litigation. (The other two pharmaceutical companies named in complaints brought by citizens of other countries are not named in the Taiwan complaints.) 1

The three Taiwan complaints are substantially similar. The parties have tended to focus in their briefs on the Chang complaint as illustrative, and, for convenience, we will refer to these Taiwan claims as the Chang case. 2

Another difference between Chang and the rest of the cases in the MDL is that Chang alleges not only the tortious conduct that resulted in plaintiffs’ infections, but, in addition, a claim that the plaintiffs were fraudulently induced by defendants to enter into a “humanitarian agreement” (the “Humanitarian Agreement”) that purported to release any claims they might have against the defendants in return for a payment of $60,000 to each plaintiff. The allegation is that although the defendants knew at the time of the agreement that plaintiffs’ infections had been caused by the defendants’ negligent manufacture of their products, they concealed that fact from the plaintiffs and from the Taiwan Ministry of Health, which participated in the negotiations leading to the agreement and recommended to the plaintiffs that they accept the settlement. The plaintiffs do not make a claim for rescission of the agreement, but seek, rather, to recover damages, including an additional payment based on a “scale-up” provision — a provision of the agreement that calls for plaintiffs to receive additional moneys that might be necessary to make their total payments equal to any that might be received by other persons who settled their claims with the defendants. 3 (The “First Generation” claimants in this MDL settled with defendants for $100,000 per person.)

The defendants deny any fraudulent inducement or concealment and plead the Humanitarian Agreement as a settlement that bars the plaintiffs’ tort claims against them.

*860 THE LAW OF FORUM NON CONVENIENS

The defendants argue that the litigation of these claims in either of the California districts would be oppressively inconvenient for them for essentially the same reasons they have successfully moved to dismiss the other foreign claims. Taiwan, in their view, would be substantially more convenient for them and not substantially more inconvenient for the plaintiffs than California.

As we stated in Abad,

The steps involved in a forum non con-veniens analysis are well-settled. The first step is a two-part inquiry as to whether the proposed alternative forum ... is available and adequate for the litigation of plaintiffs’ claims. Kamel v. Hill-Rom Co., 108 F.3d 799, 802-03 (7th Cir.1997) (“An alternative forum is available if all parties are amenable to process and are within the forum’s jurisdiction. An alternative forum is adequate when the parties will not be deprived of all remedies or treated unfairly.”). If the alternative forum is both available and adequate, “the district court must then balance the private and public interest factors that emerge in a given case.” Id. (citations omitted).

531 F.Supp.2d at 959-60.

AVAILABILITY

The defendants agree as a condition of dismissal that they will accept service of process in Taiwan and that they will not challenge the Taiwanese court’s jurisdiction. According to the defendants’ expert witness, Peter Tuen-Ho Yang, a Taiwanese law professor, Taiwanese courts accept jurisdiction by consent (Yang Decl. ¶ 40), and plaintiffs offer no contrary opinion. Defendants also include in their motion to dismiss the additional stipulations we have found sufficient to protect the plaintiffs in Gullone, Abad and Ashkenazi. (Defs.’ Mot. to Dismiss ¶ 2.)

Despite the statement of the Seventh Circuit in Kamel, 108 F.3d at 802, that “[a]n alternative forum is available if all parties are amenable to process and are within the forum’s jurisdiction,” the Chang

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Robin Orr v. Bank of America, Nt & Sa
285 F.3d 764 (Ninth Circuit, 2002)
United States Liability Insurance v. Haidinger-Hayes, Inc.
463 P.2d 770 (California Supreme Court, 1970)
Norgart v. Upjohn Co.
981 P.2d 79 (California Supreme Court, 1999)
Jolly v. Eli Lilly & Co.
751 P.2d 923 (California Supreme Court, 1988)
American Bank of Commerce v. Corondoni
169 Cal. App. 3d 368 (California Court of Appeal, 1985)
Ashland Chemical Co. v. Provence
129 Cal. App. 3d 790 (California Court of Appeal, 1982)
In Re Factor Viii or Ix Concentrate Blood Prods.
531 F. Supp. 2d 957 (N.D. Illinois, 2008)
Younis v. American University in Cairo
30 F. Supp. 2d 390 (S.D. New York, 1998)
Kontoulas v. A.H. Robins Co.
745 F.2d 312 (Fourth Circuit, 1984)

Cite This Page — Counsel Stack

Bluebook (online)
595 F. Supp. 2d 855, 2009 U.S. Dist. LEXIS 3023, 2009 WL 89873, Counsel Stack Legal Research, https://law.counselstack.com/opinion/in-re-factor-viii-or-ix-concentrate-blood-products-liability-litigation-ilnd-2009.